Treatment of RSV with combination product

US11369612B2 · kind B2 · utility

Assignee

• Janssen Sciences Ireland Unlimited Company · IE

Inventors

• Nina Ysebaert · Beerse, BE
• Nele Isa E. Goeyvaerts · Kuringen, BE
• Dirk André Emmy Roymans · Turnhout, BE
• Anil Koul · Edegem, BE

Key dates

• Filing date: Dec 4, 2018
• Grant date: Jun 28, 2022
• Expiry date: Dec 14, 2038

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P31/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention is directed to the combination of the RSV inhibiting Compound A, i.e. 3-({5-chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl}methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one, and the RSV inhibiting Compound B, i.e. (1S,2S)-2-[4-[7-cyclopropyl-5-[(1R)-1-methyl-3,4-dihydro-1H-isoquinoline-2-carbonyl]pyrazolo[1,5-a]pyrimidin-2-yl]-3-fluoro-phenyl]cyclopropanecarboxylic acid for treating or ameliorating RSV infection. The invention further relates to the combination product of Compound A and Compound B, a pharmaceutical product comprising Compound A and Compound B, the use of the combination of Compound A and Compound B—or the pharmaceutical product comprising Compound A and Compound B—for the treatment of RSV infection, and a method of treating or ameliorating RSV infection in a subject in need thereof comprising administering the combination of Compound A and Compound B in an effective amount to said subject.